Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage

World Journal of Gastroenterology

Volumn 12, Issue 35, 2006, Pages 5692-5698

  Derbala, Moutaz F ^a   Al Kaabi, S R ^a   El Dweik, N Z ^a   Pasic, F ^a   Butt, M T ^a   Yakoob, R ^a   Al Marri, A ^a   Amer, A M ^a   Morad, N ^a   Bener, A ^a  

^a HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

Bilharziasis; Genotype 4; Hepatitis C virus; Pegasys

Indexed keywords

PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN;

ADULT; AGE; ANEMIA; ARTICLE; BODY WEIGHT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EGYPT; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GENOTYPE; HEMATOLOGIC DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUTROPENIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHISTOSOMIASIS; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; THYROID DISEASE; VIRUS LOAD; WEIGHT REDUCTION;

EID: 33750100192     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i35.5692     Document Type: Article

References (37)

1. Farci P, Purcell RH. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis 2000; 20: 103-126
2. Lyra AC, Ramrakhiani S, Bacon BR, Di Bisceglie AM. Infection with hepatitis C virus genotype 4 in the United States. J Clin Gastroenterol 2004; 38: 68-71
3. el-Zayadi A, Simmonds P, Dabbous H, Prescott L, Selim O, Ahdy A. Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4. J Viral Hepat 1996; 3: 261-264
4. Shobokshi O, Serebour FR, Skakni L, Al Jaser N, Tantawe AO, Sabah A, Dinish T, Qatani T, Sandokji A, Al-Blowi A, Karawi M, Al-Kayyal B, Al-Momen S, Akbar H, Ayoola A, El-Hazmi M, El-Hazmi M, Humaida A, Eissa H, Al-Quaiz M, Khawajah F, Al-Khalifa M. Peg-IFN Alfa-2a (40kda) As A Monotherapy or In Combination With Ribavirin Significantly Improve End of Treatment Response Rate. In: HCV Genotype 4 Chronic Active Hepatitis (CAH) Patients. 53rd AASLD 2002. Boston, MA. Hepatology 2002; 36: 2
5. Gad A, Tanaka E, Orii K, Rokuhara A, Nooman Z, Serwah AH, Shoair M, Yoshizawa K, Kiyosawa K. Relationship between hepatitis C virus infection and schistosomal liver disease: not simply an additive effect. J Gastroenterol 2001; 36: 753-758
6. Helal TE, Danial MF, Ahmed HF. The relationship between hepatitis C virus and schistosomiasis: histopathologic evaluation of liver biopsy specimens. Hum Pathol 1998; 29: 743-749
7. Shiha G, Zalata KR. Does schistosomiasis interfere with application of the Knodell score for assessment of chronic hepatitis C? Med Sci Monit 2002; 8: CR72-77
8. Hassan MI, Kassim SK, Ali HS, Sayed el-DA, Khalifa A. Evaluation of nitric oxide (NO) levels in hepatitis C virus (HCV) infection: relationship to schistosomiasis and liver cirrhosis among Egyptian patients. Dis Markers 2002; 18: 137-142
9. Sherman M. Response To Pegasys And Regular Interferon A-2a For Individuals With Chronic HCV And Genotype 4. Virologic Response To Pegasys With Genotype 4 In Small Study Group. AASLD November 2000. Hepatology 2002; 42 Suppl 1: 1A-32A
10. Shiffman ML. Pegylated interferons: what role will they play in the treatment of chronic hepatitis C? Curr Gastroenterol Rep 2001; 3: 30-37
11. Hadziyannis SJ, Papatheodoridis Gv. Recent Peginteferon And Ribavirin Combination Trials. Current Hepatitis Reports 2004; 3: 30-37
12. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
13. Brau N. Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C. J Viral Hepat 2004; 11: 191-197
14. Xie Y, Xu DZ, Lu ZM, Luo KX, Jia JD, Wang YM, Zhao GZ, Zhang SL, Zhang DZ. Predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open, and multi-center controlled trial. Hepatobiliary Pancreat Dis Int 2005; 4: 213-219
15. Pawlostky J, Hezode C, Pellegrin B, Soulier A, Monder H. Early Hcv Genotype 4 Replication Kinetics During Treatment With Peginterferon Alpha-2a (Pegasys)-Ribavirin Combination. A Comparison Study with Hcv Genotype 1 And 3 Kinetics. Hepatology 2002; 36: 291A
16. Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, Perelson AS, Layden TJ. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 28-35
17. Thakeb F, Omar M, El Awady M, Ishak S. Randomized Controlled Trial Of Peginterferon Alfa-2a Plus Ribavirin For Chronic Hepatitis C Virus-Genotype 4 Among Egyptian Patients. Abstract. Hepatology 2003; 38; 278A
18. Shobokshi OA, Serebour FE, Skakni L, Al Khalifa M: Combination Therapy Of Peginterferon Alfa-2a (40kd) (Pegasys®) And Ribavirin (Copegus®) Significantly Enhance Sustained Virological And Biochemical Response Rate In Chronic Hepatitis C Genotype 4 Patients In Saudi Arabia. Abstract. Hepatology 2003; 38: 996A
19. Diago M, Hadziyannis S, Bodenheimer H, Hassanein T, Uchman S, Marcellin P, Ramadori G, Delwaide J, Sedarati F. Optimized Virological Response In Patients With Genotype 4 Chronic Hepatitis C Treated With Peginterferon Alfa-2a (40KD) (Pegasys®) In Combination With Ribavirin (RBV) (Abstract). Hepatology 2002; 36: 364A
20. Derbala M, Omar M. Efficacy of Interferon Therapy For Hepatitis C Virus In Patients With Schistosomiasis. Results from a Comparative Study. Kasr AL Aini Med J 1998; 4 Suppl 1: 247-254
21. Derbala M, Amer A, Bener A, Lopez AC, Omar M, El Ghannam M. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat 2005; 12: 380-385
22. Foster GR. Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004; 20: 825-830
23. Di bisceglie A, Rustgi V, Thuluvath P, davis M, Ghalib R, Lyons M, Ondovik M, Lopez-Talavera J, Hamzeh F. Pharmacokinetics and pharmakodynamics of pegylated interferon-alpa2a with ribavirin in treatment naive patients with genotype 1 chronic hepatitis. 55th AASLD 2004. Boston, MA, Abstract LB-18
24. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37: 1351-1358
25. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Chaneac M, Reddy KR. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425-433
26. Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, Saleh WA, Ismail A, Aziz AA, Madwar MA. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 34: 858-866
27. Ticehurst J, Hu S, Hamzeh F, Thomas D. Factors affecting hcv viral load in patients with genotype 1 infection (Abstract 411). Hepatology 2004; 40 Suppl: 342A
28. Al-Faleh FZ, Aljumah A, Rezeig M, Al-Kanawi, Al-Otaibi M, Alahdal M, Al-Humayed S, Mayet I, Al-Juhani M, Al-Karawi M, George K, Sbeih F. Treatment of chronic hepatitis C genotype IV with interferon-ribavirin combination in Saudi Arabia: a multicentre study. J Viral Hepat 2000; 7: 287-291
29. Heathacote EJ, Mitchell L, Shiffman W. peginterferon alpha-2a in patients with chronic hepatitis c and cirrhosis. N Engl J Med 2000; 343: 1673-1680
30. Marcellin P, Roberts S, Alberti A, Trepo C, Zeuzem S, Hoel Sette Jr, Brouwer J.sustained virological and biochemical response to peginterferon alpha-2a plus ribavirin in patients with chronic hepatitis c and compensated cirrhosis/bridging fibrosis. Hepatology 2004; 40: 531A
31. Tsubota A, Arase Y, Someya T, Suzuki Y, Suzuki F, Saitoh S, Ikeda K, Akuta N, Hosaka T, Kobayashi M, Kumada H. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2005; 75: 27-34
32. Picciotto A, Campo N, Brizzolara R, Sinelli N, Poggi G, Grasso S, Celle G. HCV-RNA levels play an important role independently of genotype in predicting response to interferon therapy. Eur J Gas troenterol Hepatol 1997; 9: 67-69
33. El-Kady IM, Lotfy M, Badra G, El-Masry S, Waked I. Interleukin (IL)-4, IL-10, IL-18 and IFN-gamma cytokines pattern in patients with combined hepatitis C virus and Schistosoma mansoni infections. Scand J Immunol 2005; 61: 87-91
34. Elrefaei M, El-sheikh N, Kamal K, Cao H. Analysis of T cell responses against hepatitis C virus genotype 4 in Egypt. J Hepatol 2004; 40: 313-318
35. Dieterich DT, Spivak JL. Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003; 37: 533-541
36. Patel K, Anouk T. Adherence to antiviral therapy in chronic hepatitis. Current hepatitis reports 2004; 3: 10-15
37. Homoncik MG, Sieghart W, Formann E, Schmid M, Ferlitsch A, Ferenci P, Gangl A, Jilma B, Peck-Radosavljevic M. Erythropoietin and platelet counts, platelet function in patients with chronic hepatitis c undergoing combination antiviral therapy: a randomized, placebo-controlled, double-blind study (Abstract 527). Hepatology 2004; 40 suppl 1: 392A